MELPHALAN HYDROCHLORIDE

Post-LOE

melphalan hydrochloride

Hetero

ANDAINJECTIONINJECTABLE

Approved

Feb 2020

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

4/8 — Partial

MELPHALAN HYDROCHLORIDE (melphalan hydrochloride) by Hetero is clinical pharmacology melphalan is an alkylating agent of the bischloroethylamine type. Approved for myeloma. First approved in 2020.

Drug data last refreshed 20h ago

Mechanism of Action

CLINICAL PHARMACOLOGY Melphalan is an alkylating agent of the bischloroethylamine type. As a result, its cytotoxicity appears to be related to the extent of its interstrand cross-linking with DNA, probably by binding at the N position of guanine. Like other bifunctional alkylating agents, it is…

Worked on MELPHALAN HYDROCHLORIDE at Hetero? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

MELPHALAN HYDROCHLORIDE

Mechanism of Action

Indications (1)

Clinical Trials (1)